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Abstract 
Background: The aim of this study was to evaluate the effects of intermittent treatment of parathyroid hormone 
(PTH (1-34)) on the bone regeneration of critically-sized rat calvarial bone defects. 
Material and Methods: Thirty-two male rats were trephined (4mm fullthickness diameter), in the central part 
of the parietal bones and divided into 2 groups of 16. The PTH group received subcutaneous injections of PTH 
(1-34) at 40µg/kg, 3 times a week and the control (CTL) group received the vehicle in the same regimen. The rats 
were sacrificed at 4 weeks post-treatment regimen, the parietal bones were extracted and samples were evaluated 
through histomorphometry and radiodensitometry.
Results: The histological observations showed that the PTH group presented more “island-like” new bone between 
the defect margins with fibrous tissues than did the CTL group. The PTH group significantly exhibited greater his-
tologic bone formation than did the CTL group (1.5mm ±0.7; 1.9 mm ± 0.6, p<0.05/ for residual bone defect). The 
radiodensitometry analysis revealed significant differences among the PTH and CTL groups (2.1 Al eq. ±0.04; 
1.8Al eq. ±0.06, p<0.05), demonstrating an increase in bone mineral density. The PTH treatment contributed to 
the bone formation with a higher amount of mineral and/or fibrous tissue when compared with the CTL group.
Conclusions: The results suggest that it was possible to increase the process of bone regeneration by accelerating 
the healing process in rat calvarial defects through intermittent administration of the PTH treatment.
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Introduction
Defects in bone are frequent sequelae of pathological 
conditions such as tumors, cysts, infections, trauma 
or surgery. The slow regeneration of bone in such de-
fects can pose therapeutic problems. Various strategies 
to stimulate healing of bone defects have been tested. 
These include autografting and allografting of bone, 
application of growth factors, polymeric membranes, 
enamel matrix derivative and others (1-3).
Various drugs have been used to assist in bone regen-
eration, in a way stimulate bone tissue anabolism (4,5). 
We have demonstrated that the PTH intermittent treat-
ment was able to prevent or minimize bone loss caused 
by induced periodontitis in rats (6,7) and also improved 
the healing fenestration bone defect in rat mandible (8) 
PTH functions as a major mediator of bone remodeling 
and as an essential regulator of calcium homeostasis, 
producing several distinct and independent effects on 
bone remodeling process, resulting in both bone forma-
tion (anabolic activity) and bone remodeling (catabolic 
activity), e.g. the continuous administration of PTH is 
characterized by large numbers of osteoclasts and en-
hanced osteoclast activity, rapid turnover and decrease 
of bone mass, while intermittent administration in-
creases bone mass by stimulating osteoblast differen-
tiation and prevention of osteoblast apoptosis (9).
PTH has been used successfully in the treatment of os-
teoporosis in humans. Intermittent administration of 
PTH has been proved to decrease the risk of vertebral 
and non-vertebral fractures and to increase the femoral 
and vertebral bone density with reduced or absent side 
effects (10). Studies have also demonstrated that the in-
termittent PTH treatment enhances fracture strength 
and callus amount in the healing of tibial fractures in 
rats (11), also increasing stiffness, bone density and the 
ultimate load in newly-formed bone after osteogenesis 
distraction in rats (12). Although most of these studies 
support a role for PTH in the treatment of osteoporosis 
and long bone fractures, only a few studies associated 
PTH treatment to calvarial healing (13,14).
Andreassen and Cacciafesta (14) reported that intermit-
tent PTH administration enhanced mechanical strength 
of healing rat calvarial defects covered by expanded 
polytetrafluoroethylene membranes, besides having in-
creased the dry weight of the newly-formed tissue in-
side the defect.  Stancoven et al. (13) used a critical-size 
of 8mm and investigated the potential of recombinant 
human bone morphogenetic protein-2 soak-loaded onto 
an absorbable collagen sponge to induce local bone for-
mation compared with the clinical reference deminer-
alized bone matrix and investigated potential additive/
synergistic effects of exogenous PTH. 
The purpose of our study was to evaluate the effect of 
intermittent PTH treatment alone on critically-sized 
calvarial defects (4mm) in Wistar rats through histo-
morphometric and radiodensitometric analyses.
Material and Methods
- Animals 
Thirty-two male Wistar rats, weighing an average of 250 
g, were used in this study. The animals were separated 
randomly into two groups (16 rats per group) and kept 
in cages in an animal room having a photoperiod of 12 h 
of light with access to industrial food, close to 110 Kcal/
kg of body weight; water was provided “ad libitum.” 
Room temperature was kept at between 22-25°C, and 
animals were allowed one week to adapt to the environ-
ment. The University of Campinas Institutional Animal 
Care and Use Committee approved the protocol under 
number 737-2/ UNICAMP-CEEA-IB-UNICAMP.
- Surgical Technique
The animals were anesthetized with intramuscular ad-
ministration of a solution of 13 mg/Kg of 2% xylazine 
hydrochloride (Rompum-Bayer-São Paulo, SP, Brazil) 
and 33 mg/Kg of ketamine (Francotar-Virbac-Roseira, 
SP, Brazil). During surgery, local anesthesia (lidocaine, 
1:100.000 epinephine) was used at the surgical site to 
reduce local bleeding.
The surgical site was trichotomized and scrubbed with 
iodine. An incision approximately 20mm long was made 
in the scalp along the sagittal suture and full-thickness 
flap, including periosteum, was reflected, exposing the 
calvarial bone. Afterwards, two transosseous defects 
standardized with 4mm each in diameter were created 
in the center of the parietal bone without damaging the 
dura mater. A 4mm trephine bur (Neodent, Curitiba, 
PR, Brazil) was used to create the defects under con-
stant irrigation with sterile physiological solution, to 
prevent the overheating of bone margins. The perios-
teum and skin were then sutured for total coverage us-
ing 4-0 nylon point sutures (Ethicon, Johnson & John-
son, São José dos Campos, SP, Brazil).
Three days after surgery, the animals were divided into 
2 groups of 16 animals each. To the experimental group, 
PTH group, 40µg/kg of PTH was given (1-34) (Sigma-
Aldrich, St. Louis, MO) prepared in 1% acetic acid, in-
jected subcutaneously, 3 times a week for 4 weeks. The 
control group (CTL group) received the same volume of 
the vehicle according to figure 1. The intermittent PTH 
schedule and dose used in the present study were based 
on previous study (6-8). Neither antibiotics nor anti-in-
flammatory drugs were administered after the surgery. 
Acetaminophen (Paracetamol, Abbott Laboratories, São 
Paulo, São Paulo, Brazil) was used for pain control.  
- Radiographic Procedures
After 4 weeks of treatment, the animals were sacrificed 
through overdose of anesthetics. Sections of bone tis-
sue, including the surgical sites, were removed with 
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701bur (Neodent, Curitiba, PR, Brazil) under constant 
irrigation and fixed in 4% neutral formalin solution for 
72h. All samples were radiographed using a dental x-ray 
unit (GE-1000) with an exposure time of 0.1 seconds 
and 31x41mm dental radiographic film (Insight Film, 
Eastman Kodak, Rochester, NY) and radiographs were 
densitometrically measured through aluminum step-
wedge equivalent thickness (Al eq.). The mean values of 
an optical density were obtained from 5 measurements 
of the defect area.
- Histological Procedures
After the radiographic procedures, all samples were 
demineralized in a 5% EDTA/phosphate buffered sa-
line solution for 60 days and embedded in paraffin (15). 
Five-µm thick sections including the center of circu-
lar defects were stained with Hematoxylin and Eosin. 
Paraffin serial sections were measured using an image 
analysis system (Image-Pro, Media Cybernetics, Sil-
ver Spring, MD and Program KS400, Kotron Elektron 
GmbH, Eching, Germany). The residual bone defect 
was defined as the distance of the bone margins after 
the treatment period (Fig. 2A). In the presence of areas 
of new bone formation between the margins, the total 
measurement was calculated deducting the new bone 
island-like formations (Fig. 2B).
- Statistical Analysis
Student’s t test was used for the comparison between 
experimental and control groups. The data were submit-
ted to statistical analysis and p values lower than 0.05 
were considered significant (BioEstat ver.5.0, Belém, 
PA, Brazil).
Results
- Clinical observations
No adverse events were observed during the healing in-
terval. After 4 weeks, the defects in PTH group were 
smaller and the edges were more irregular than in the 
CTL group. Bone regeneration occurred in form of 
islands-like, more evident characteristics in the PTH 
group (Fig. 2D) compared to the CTL group (Fig. 2C). 
Neither of the specimens exhibited osseous continuity 
in both edges of the defect after treatment for 4 weeks.
- Histological Findings
The histological observations through light microscopy 
showed that in the PTH group, the bone defects were 
filled with new bone formation and thick fibrous tissue 
(Fig. 2B, D and Fig. 3B). In comparison, the CTL group 
showed that the bone defect was filled mainly with fi-
brous tissue (Fig. 3A) and a little island-like new bone 
formation between the margins of the initial defect (Fig. 
2C).
Bone Histomorphometric Analysis
The histomorphometric analysis of the residual defect 
showed that samples from the PTH group presented 
mean of 1.5mm ±0.7 in diameter; for the CTL group, 
Fig. 1. Animal Experiments demonstrate the adaptation time, begin-
ning treatments (PTH and CTL groups), surgery (Calvaria defects), 
and the time of sacrifice.
Fig. 2. Photomicrographs illustrating the section of critically-
sized defect in calvaria of Wistar rat from different groups stained 
with hematoxylin and eosin. A) Black line indicates residual bone 
defect measured in CTL group (original magnification 35x). B) 
Black line indicates residual bone defect measured in PTH group 
(original magnification 35x). C) Arrowheads indicate fibrous tis-
sue and arrow indicates island-like of new bone in the CTL group 
(original magnification 35x). D) Arrowheads indicate fibrous tis-
sue and arrows indicate island-like of new bone in the CTL group 
(original magnification 25x). β = Bone.
Fig. 3. Photomicrographs of defect in calvaria of Wistar rat from 
different groups stained with hematoxylin and eosin, original 
magnification 600x. Histological details of the CTL group in A 
and PTH group in B. Arrowheads indicate osteoblasts, FT = fi-
brous tissue, β = Bone.
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the mean diameter was 1.98mm ±0.6 at 4 weeks post-
surgery. There were statistically significant intergroup 
differences (p< 0.05). 
Radiodensitometric Analysis
Statistical analysis (p<0.05) of optical density revealed 
significant differences among the PTH group (2.1Al eq. 
±0.04) and the CTL group (1.8Al eq. ±0.06).
Discussion
Recombinant human PTH (1-34) has been approved in 
the United States as monotherapy for the treatment of 
postmenopausal women with osteoporosis. Since PTH 
has been approved for the treatment of osteoporosis, a 
number of questions have arisen and PTH, in combi-
nation with other antiresorptive agents, has also been 
used for the treatment of osteoporosis (16-18). Howev-
er, clinical administration of PTH alone is a potential 
therapy that has been shown to enhance and accelerate 
bone formation in bone fractures, regions surrounding 
dental implants (19,20) and in fenestrated mandibular 
defect (8).
The critically-sized bone defect has been defined as the 
size of an osseous defect that does not heal spontane-
ously with bone during the lifetime of the animal (21). 
Aalami et al. (22) demonstrated that the full-thickness 
3, 4 and 5mm diameter in mice s´ calvarial defect is not 
completely healed after 8 weeks. 
In this study, we used a critically-sized 4mm calvarial 
defect in rats that were ten weeks old in the begging of 
the experiment. The treatment with intermittent PTH 
administration was given for 4 weeks and as expected, 
in both groups, PTH and CTL, there was an incomplete 
healing of the defects in this period studied. However, 
it was possible to observe the presence of new bone for-
mation as islands-like between the margins of the initial 
4mm defect.
It has been demonstrated that with the PTH intermit-
tent treatment, it was possibly to prevent bone loss and 
restore bone mass in ovariectomized rats (23). Shirota 
et al. (20) evaluated the influence of intermittent PTH 
(1-34) administration on the healing process after the 
placement of titanium screw implants in ovariectomized 
rats. The authors found that the density of bone around 
implants in the PTH group was almost the same found 
in the Sham operated group after 56 days of implanta-
tion, suggesting that the PTH treatment might be useful 
to improve clinical results after dental implantation.
Our previous work showed that the PTH (1-34) treat-
ment using 40 µg/kg, 3 times a week, was able to pro-
tect the tooth site from periodontitis-induced bone loss 
and promoted significant reduction in the number of 
inflammatory cells at the marginal gingival area in ova-
riectomized rats (6,7).
Another investigation of our research team (8) demon-
strated the PTH (1-34) administration was effective to 
induce bone formation, increase bone density, increase 
the amount of callus formed and also to accelerate the 
callus reabsorption, an increase in the number of osteo-
clasts present in the callus region, corroborating with 
other studies (9,12-14,24).
We also investigated the bone mineral density (BMD) 
that is widely used to evaluate alterations in the bal-
ance between osteoblastic bone formation and osteo-
clastic bone resorption (25). The measurement of BMD 
through radiographic densitometry has been performed 
in a number of studies, and its efficacy has been con-
firmed (25-27). Radiographic densitometry analysis is 
an important tool for the research evaluation because it 
is a rapid and low-cost method, and can produce results 
which are similar to those of dual-energy x-ray absorp-
tiometry (25).
Our study was the first to use radiographic densitome-
try for the analysis of the intermittent PTH treatment in 
calvarial defect. We demonstrated that the PTH (1-34) 
intermittent treatment increased the BMD in rat calvar-
ia critically-sized defect model. These results reinforce 
the histological observations due to, possibly a specula-
tion, bone collagen during the mineralization phase, and 
changes in bone turnover could be expected to affect 
the quality of the bone, corroborating in a similar way 
with our previous study observed in the characteristics 
of collagen fibers from the periodontal ligament visual-
ized through polarizing light microscopy (8). Garnero 
et al. (28) demonstrated that the PTH treatment changed 
type-I collagen isomerization (28).
Stancoven et al. (13) demonstrated that with PTH (1-34) 
administered (15 µg/kg) daily on calvarial defect (8mm) 
analyzed through radiographic and histologic exams, 
bone formation was slightly increased in the PTH group 
without a membrane and in the PTH group with a mem-
brane. Andreassen and Cacciafesta (14) reported that 
daily PTH (1-34) administration (60µg/kg) for 5 weeks 
enhanced mechanical strength of healing rat s´ calvarial 
defects (5mm) covered with expanded polytetrafluor-
oethylene membranes, and increased the dry weight of 
the newly-formed tissue inside the defect.
We demonstrated that treatment with a lower frequency 
of PTH injections, 3 times a week, for 4 weeks using 
dose PTH at 40µg/kg, was able to contribute to the ac-
celeration of the healing process in the absence of some 
type of membrane to isolate the defect (4mm). We also 
demonstrated an increase in optical density measure-
ments (bone mineral density) in the PTH group; sam-
ples suggested that PTH treatment contributed to bone 
formation with a higher amount of mineral and/or fi-
brous tissue when compared with the CTL group. These 
results were associated with the frequent observation of 
“island-like” format of new bone in the PTH group and 
a possible organization of the new collagen fibers, as 
previously demonstrated (8,28).
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In conclusion, the present study reinforced the anabolic 
potential of PTH (1-34) intermittent treatment alone, 
without the utilization of any coadjuvant, suggesting 
that it is possible to increase the process of bone regen-
eration by accelerating the healing process in rat s´ cal-
varial defects.
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